Therefore, our findings suggest that it is imperative to perform a clinical trial of midostaurin alone or in combination with rituximab, preferably for relapsed/refractory BL patients and possibly for other relapsed/refractory NHL patients with highly activated PKC. The gene discussed is PRRT2; the disease is Burkitt lymphoma.